Vost Effectiveness of Blinatumomab Vs Inotuzomab Ozogamicin (INOTUZUMAB) in Adult Patients with Relapsed or Refracory (R/R) Acute Lymphoblastic Leukemia (ALL) with Zero or One Prior Salvage Therapy (S0/S1) from a US Payer Perspective
Abstract
Authors
TE Delea X Zhang J Amdahl D Boyko F Severin M Campioni Z Cong